한빛사 논문
Abstract
Seulki Lee†‡¤, Ju Hee Ryu†¤, Kyeongsoon Park†, Aeju Lee†, Seung-Young Lee†, In-Chan Youn†, Cheol-Hee Ahn§, Soon Man Yoon∥, Seung-Jae Myung∥, Dae Hyuk Moon∥, Xiaoyuan Chen‡, Kuiwon Choi†, Ick Chan Kwon† and Kwangmeyung Kim*†
Biomedical Research Center, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791, Korea, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, School of Materials Science and Engineering, Seoul National University, 599 Gwanangno, Gwanak-gu, Seoul 151-742, Korea, and Asan Medical Center, University of Ulsan College of Medicine, 388-2 Pungnap2-dong, Songpa-gu, Seoul 138-736, Korea
† Korea Institute of Science and Technology.
‡ National Institute of Biomedical Imaging and Bioengineering.
¤ These authors contributed equally to this work.
§ Seoul National University.
∥University of Ulsan College of Medicine.
* To whom correspondence should be addressed. Phone: +82-2-958-5916. Fax+82-2-958-5902.
Abstract
We report here a new protease activatable strategy based on a polymer nanoparticle platform. This nanosensor delivers chemically labeled matrix metalloproteinase (MMP)-activatable fluorogenic peptides to the specific MMPs of interest in vivo. Intravenous administration of the nanosensor in an MMP-positive SCC-7 xenograft tumor and a colon cancer mouse model verified the enzyme specificity of the nanosensor in vivo. The design platform of the nanosensor is flexible and can be fine-tuned for a wide array of applications such as the detection of biomarkers, early diagnosis of disease, and monitoring therapeutic efficacy.
Nano Lett., Article ASAP
DOI: 10.1021/nl902709m
Publication Date (Web): October 20, 2009
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기